Y-Intercept (HK)’s Mustang Bio MBIO Stock Holding History

Y-Intercept (HK)’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16	Closed	-$7K	–	1148
2022 Q2	$7K	Buy	+16	New	+$8.86K	﹤0.01%	820

Other funds holding MBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Y-Intercept (HK)'s MBIO Position: Q3 2022 in Review

Y-Intercept (HK) sold out of Mustang Bio (MBIO) in Q3 2022, closing a stake of 16 shares — an estimated $7K sold.

Y-Intercept (HK) first reported a position in MBIO in Q2 2022 and held it in 1 quarter. The position peaked at $7K in Q2 2022. 67 funds tracked by Wall St. Rank hold MBIO as of Q3 2022.

Y-Intercept (HK) reported no remaining Mustang Bio position as of Q3 2022 after selling out during the quarter.
Y-Intercept (HK) sold 16 Mustang Bio shares in Q3 2022, an estimated $7K.
Y-Intercept (HK) first reported a position in Mustang Bio in Q2 2022 and held it in 1 quarter.
Y-Intercept (HK)'s Mustang Bio position peaked at $7K in Q2 2022.
67 funds tracked by Wall St. Rank held Mustang Bio as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.